New Cancer Drug Trials Show Promise for Patients with KRAS Gene Mutation

Scientists testing a class of drugs called selective KRASG12D inhibitors — medicines designed to block a faulty version of a protein that can drive cancer growth — have reported promising outcomes in patients with advanced tumours carrying the G12D mutation. The findings, presented in a News and Views piece by Jennifer Knox and colleagues in the journal Nature Medicine, suggest the approach could eventually apply across different cancer types and at various stages of the disease.

The KRAS gene, when mutated, produces a protein that tells cancer cells to keep dividing. The G12D variant is one of the most common of these faults, appearing in cancers including pancreatic, bowel and lung cancer. Until recently, KRAS mutations were considered almost impossible to target with drugs — so any treatment that can selectively block them is a notable development in cancer research.

Nature Medicine describes the results as signalling a major shift in how these cancers might be treated. But the research is at an early stage, and it is not yet clear when — or whether — these drugs will become part of routine NHS treatment in the UK.

Patients with questions about their own cancer care or genetic test results should speak to their oncology team or GP rather than drawing conclusions from early trial data.

Key information

• Speak to your GP or hospital specialist if you have concerns about a cancer diagnosis or treatment options
• NHS 111 is available 24 hours a day for general health queries
• The Macmillan Cancer Support helpline can be reached on 0808 808 00 00